Core Viewpoint - BioVie is actively engaging with investors through a presentation led by its President and CEO, Cuong Do, highlighting the company's strategic direction and future prospects [1]. Company Overview - BioVie trades on NASDAQ under the ticker symbol "BioVie" [1]. - The event is organized by Redchip Companies, indicating a focus on investor relations and market engagement [1]. Future Outlook - The presentation may include forward-looking statements regarding financial and operational results, reflecting management's expectations and strategic goals [1]. - The company acknowledges that these forward-looking statements involve inherent risks and uncertainties, which are typical in the biotech sector [1].

Core Insights - BioVie Inc. presented findings on Bezisterim, indicating its potential to decrease biological age acceleration in Alzheimer's Disease by modulating DNA methylation of over 100 genes related to aging and diseases of aging [1][4]. Group 1: Bezisterim's Mechanism and Effects - Bezisterim modulates TNFα-driven inflammation, helping to reestablish homeostasis and affecting multiple genes simultaneously [4]. - The treatment resulted in significant age deceleration across various biological clocks after 30 weeks, including reductions of -3.16 years for SkinBloodClockAge and -4.12 years for PhenoAge [5]. - Bezisterim demonstrated modulation of inflammatory gene expression, reducing levels of inflammatory cytokines such as TNFα, IL-6, and IL-17 [5]. Group 2: Clinical Trials and Efficacy - BioVie is conducting ongoing studies to explore Bezisterim's potential in improving healthspan in normal aging and its effects on neurodegenerative diseases [4]. - In Alzheimer's Disease, Bezisterim-treated patients showed improved cognition and biomarker levels in a Phase 2 trial, with significant improvements in metabolic and inflammatory biomarkers compared to placebo [10][11]. - The company is also enrolling patients in a Phase 2 trial for Parkinson's Disease, with topline data expected in late 2025 or early 2026 [8]. Group 3: Safety and Tolerability - Bezisterim is not immunosuppressive and has shown favorable safety and tolerability profiles in clinical trials for Alzheimer's Disease and Parkinson's Disease [6][7].